Innovent Biologics Inc - ESG Rating & Company Profile powered by AI
Full Sustainability assessment of Innovent Biologics Inc can be reached by logging in. The article includes a Q&A table for Innovent Biologics Inc. If you work at Innovent Biologics Inc and you would like to use your Sustainability aseessment, please contact us.
Innovent Biologics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 6.9, social score of 5.7 and governance score of 8.0.
6.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 355 | Xbrane Biopharma AB | 7.0 | High |
| 355 | Xenetic Biosciences Inc | 7.0 | High |
| 387 | Innovent Biologics Inc | 6.9 | High |
| 387 | Advanced Medical Solutions Group PLC | 6.9 | High |
| 387 | Acrux Ltd | 6.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Innovent Biologics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Innovent Biologics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Innovent Biologics Inc report the average age of the workforce?
Sign up for free to unlockDoes Innovent Biologics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Innovent Biologics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Innovent Biologics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Innovent Biologics Inc offer flexible work?
Sign up for free to unlockDoes Innovent Biologics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Innovent Biologics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Innovent Biologics Inc conduct supply chain audits?
Sign up for free to unlockDoes Innovent Biologics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Innovent Biologics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Innovent Biologics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Innovent Biologics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Innovent Biologics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Innovent Biologics Inc disclose water use targets?
Sign up for free to unlockDoes Innovent Biologics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Innovent Biologics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Innovent Biologics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Innovent Biologics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Innovent Biologics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Innovent Biologics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Innovent Biologics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Innovent Biologics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Innovent Biologics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Innovent Biologics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Innovent Biologics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Innovent Biologics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Innovent Biologics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Innovent Biologics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Innovent Biologics Inc disclose its waste policy?
Sign up for free to unlockDoes Innovent Biologics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Innovent Biologics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Innovent Biologics Inc disclose energy use targets?
Sign up for free to unlockDoes Innovent Biologics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Innovent Biologics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Innovent Biologics Inc
These potential risks are based on the size, segment and geographies of the company.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.